COMPARISON OF EFFICACY OF FIVE VARIOUS COMMERCIAL PRODUCTS OF CIPROFLOXACIN AGAINST STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSAAbstract
A study was undertaken to evaluate the efficacy of five various commercial products of ciprofloxacin (a broad spectrum antibiotic), manufactured by different pharmaceutical companies. The drug was evaluated for their performance based on equivalent MIC breakpoint, which is a measure of efficacy of drugs against Staphylococcus aureus ATCC6538 and Pseuomanas aeruginosa ATCC25668 when tested in vitro.The data showed variation for all manufacturers with significant difference (p <0.0001) in efficacy of these drugs at the final dilution level (0.02-0.1µg/µl) against P.aeruginosa. Thus the ciprofloxacin, prepared by various manufacturers are not equally efficacious in inhibiting the growth of S.aureus and P.aeruginosa. Therefore, manufacturers should pay special attention for stringent quality control of drug, and clinicians are suggested to use these antibiotics judiciously in the treatment of patients for these infections.
Vivek Kumar Shrivastav 1, Deepali Shukla ,Ashamukul Jana and Archana Shrivastav*
Professor and Head, Department Of Microbiology, College of Life Sciences, Cancer Hospital & Research Institute Campus, Mandre Ki Mata, Gwalior- 474009, Madhya Pradesh, India
25 October, 2012
17 December, 2012
21 January, 2013
01 February, 2013